Discovery of potent and highly selective thienopyridine Janus kinase 2 inhibitors.

Developing Janus kinase 2 (Jak2) inhibitors has become a significant focus for small molecule drug discovery programs in recent years due to the identification of a Jak2 gain-of-function mutation in the majority of patients with myeloproliferative disorders (MPD). Here, we describe the discovery of a thienopyridine series of Jak2 inhibitors that culminates with compounds showing 100- to >500-fold selectivity over the related Jak family kinases in enzyme assays. Selectivity for Jak2 was also observed in TEL-Jak cellular assays, as well as in cytokine-stimulated peripheral blood mononuclear cell (PBMC) and whole blood assays. X-ray cocrystal structures of 8 and 19 bound to the Jak2 kinase domain aided structure-activity relationship efforts and, along with a previously reported small molecule X-ray cocrystal structure of the Jak1 kinase domain, provided structural rationale for the observed high levels of Jak2 selectivity.

[1]  M. Lamb,et al.  Replacement of pyrazol-3-yl amine hinge binder with thiazol-2-yl amine: Discovery of potent and selective JAK2 inhibitors. , 2010, Bioorganic & medicinal chemistry letters.

[2]  D. Morris,et al.  Anti-inflammatory activity and neutrophil reductions mediated by the JAK1/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis , 2010, Journal of Inflammation.

[3]  J. Johnston,et al.  Thrombopoietin induces tyrosine phosphorylation and activation of the Janus kinase, JAK2. , 1995, Blood.

[4]  Jon Read,et al.  Discovery of 5-chloro-N2-[(1S)-1-(5-fluoropyrimidin-2-yl)ethyl]-N4-(5-methyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine (AZD1480) as a novel inhibitor of the Jak/Stat pathway. , 2011, Journal of medicinal chemistry.

[5]  T. Boggon,et al.  Crystal structure of the Jak3 kinase domain in complex with a staurosporine analog. , 2005, Blood.

[6]  Kevan M Shokat,et al.  Features of selective kinase inhibitors. , 2005, Chemistry & biology.

[7]  M. Hines,et al.  Discovery of CP-690,550: a potent and selective Janus kinase (JAK) inhibitor for the treatment of autoimmune diseases and organ transplant rejection. , 2010, Journal of medicinal chemistry.

[8]  Stefan N. Constantinescu,et al.  A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera , 2005, Nature.

[9]  David M. Shackleford,et al.  Phenylaminopyrimidines as inhibitors of Janus kinases (JAKs). , 2009, Bioorganic & medicinal chemistry letters.

[10]  Jian Wang,et al.  Janus kinase 2 inhibitors. Synthesis and characterization of a novel polycyclic azaindole. , 2009, Journal of medicinal chemistry.

[11]  H. Kantarjian,et al.  Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. , 2010, Blood.

[12]  Sungjoon Kim,et al.  Ba/F3 cells and their use in kinase drug discovery , 2007, Current opinion in oncology.

[13]  S. Gaffen.  Signaling domains of the interleukin 2 receptor. , 2001, Cytokine.

[14]  P. Campbell,et al.  Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders , 2005, The Lancet.

[15]  Eric Vangrevelinghe,et al.  Discovery and SAR of potent, orally available 2,8-diaryl-quinoxalines as a new class of JAK2 inhibitors. , 2010, Bioorganic & medicinal chemistry letters.

[16]  Mario Cazzola,et al.  A gain-of-function mutation of JAK2 in myeloproliferative disorders. , 2005, The New England journal of medicine.

[17]  Eric Vangrevelinghe,et al.  Identification of a potent Janus kinase 3 inhibitor with high selectivity within the Janus kinase family. , 2011, Journal of medicinal chemistry.

[18]  Hua Yu,et al.  The JAK2 inhibitor AZD1480 potently blocks Stat3 signaling and oncogenesis in solid tumors. , 2009, Cancer cell.

[19]  Sandra A. Moore,et al.  Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera. , 2008, Cancer cell.

[20]  James R Kiefer,et al.  Structural and thermodynamic characterization of the TYK2 and JAK3 kinase domains in complex with CP-690550 and CMP-6. , 2010, Journal of molecular biology.

[21]  N. K. Williams,et al.  Dissecting specificity in the Janus kinases: the structures of JAK-specific inhibitors complexed to the JAK1 and JAK2 protein tyrosine kinase domains. , 2009, Journal of molecular biology.

[22]  April Chen,et al.  Relationship between Passive Permeability, Efflux, and Predictability of Clearance from In Vitro Metabolic Intrinsic Clearance , 2010, Drug Metabolism and Disposition.

[23]  L. Berry,et al.  In vitro and in vivo pharmacokinetic characterizations of AMG 900, an orally bioavailable small molecule inhibitor of aurora kinases , 2011, Xenobiotica; the fate of foreign compounds in biological systems.

[24]  Sandra A. Moore,et al.  Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. , 2005, Cancer cell.

[25]  M. Lamb,et al.  Discovery of pyrazol-3-ylamino pyrazines as novel JAK2 inhibitors. , 2009, Bioorganic & medicinal chemistry letters.

[26]  I. Behrmann,et al.  Jak1 has a dominant role over Jak3 in signal transduction through γc-containing cytokine receptors. , 2011, Chemistry & biology.